A Randomised, Double-Blind, Placebo-Controlled, Multi-Centre, Multi-National Phase II / III Follow-up Study to Assess Long-Term Efficacy and Safety of Three Different Dose Regimens of Oralgen Grass Pollen in Patients With Grass Pollen-Related Allergic Rhinoconjunctivitis (Follow-up Study to AB0602).
Phase of Trial: Phase II/III
Latest Information Update: 20 Apr 2017
At a glance
- Drugs Grass pollen allergy immunotherapy (Primary)
- Indications Grass pollen hypersensitivity; Rhinoconjunctivitis
- Focus Therapeutic Use
- 22 Jan 2009 New trial record.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History